Orexigen Therapeutic (OREX) 0.56 $OREX
Stocks To Watch: Market Update on Today's Stocks on the Move
ACCESSWIRE - Tue Mar 22, 12:00PM CDT
MIAMI, FL / ACCESSWIRE / March 22, 2016 / Top Nasdaq Stocks is issuing a report on three stocks to watch. OREX, SXE, NETE, and BBLU have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
NETE: 0.31 (-0.12), OREX: 0.56 (unch), SXE: 1.05 (-0.03), BBLU: 0.04 (-0.01)
The Zacks Analyst Blog Highlights: GW Pharma, Orexigen, Gilead and Regeneron
Zacks Equity Research - Zacks Investment Research - Thu Mar 17, 8:30AM CDT
The Zacks Analyst Blog Highlights: GW Pharma, Orexigen, Gilead and Regeneron
OREX: 0.56 (unch), GILD: 91.86 (-0.11), GWPH: 72.15 (+1.23), REGN: 360.44 (+0.76)
Orexigen Buys U.S. Rights to Contrave, Inks Deal in the EU
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 3:50PM CDT
Orexigen (OREX) has regained U.S. rights to Contrave from Takeda Pharmaceutical and inked a deal with Valeant Pharmaceuticals to commercialize the drug in the EU.
OREX: 0.56 (unch), VRX: 26.30 (-0.77), AMAG: 23.40 (+1.28)
Biotech Stock Roundup: GW Pharma Soars on Epidiolex Data, Gilead's Zydelig in Trouble?
Arpita Dutt - Zacks Investment Research - Wed Mar 16, 10:56AM CDT
Despite some positive updates from companies like GW Pharma (GWPH), the overall performance of the sector remained weak.
OREX: 0.56 (unch), VRTX: 79.49 (+1.09), GWPH: 72.15 (+1.23), GILD: 91.86 (-0.11), SRPT: 19.52 (+0.25), ABBV: 57.12 (+0.12), REGN: 360.44 (+0.76)
Valeant and Avon slump while Apple and Mead Johnson rise
AP - Tue Mar 15, 3:51PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq stock market:
DSW: 27.64 (-0.22), OREX: 0.56 (unch), VRX: 26.30 (-0.77), AVP: 4.81 (+0.11), MJN: 84.97 (-0.02), DOV: 64.33 (unch), AAPL: 108.99 (-0.57), MS: 25.01 (-0.06), VRX.TO: 34.05 (-1.05)
Valeant shocks with missed 4Q results, slashed 2016 guidance
By LINDA A. JOHNSON - AP - Tue Mar 15, 3:44PM CDT
Shares of Valeant Pharmaceuticals crashed Tuesday after the embattled drugmaker failed to reassure investors that it's getting back on track and even conceded for the first time that it's technically in danger of defaulting on its debt.
OREX: 0.56 (unch), VRX: 26.30 (-0.77), VRX.TO: 34.05 (-1.05)
Four Companies Added To Today's Stock Watchlist on Tuesday March 15, 2016
ACCESSWIRE - Tue Mar 15, 9:47AM CDT
MIAMI, FL / ACCESSWIRE / March 15, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. BLRX, OREX, SZYM, and ESI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OREX: 0.56 (unch), ESI: 3.09 (-0.02), BLRX: 1.02 (-0.01), SZYM: 2.03 (+0.21)
Orexigen Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Today to Discuss Acquisition of U.S. Rights to Contrave® (naltrexone HCl / bupropion HCl extended release) and Central and Eastern Europe Distribution Agreement with Valeant
PR Newswire - Tue Mar 15, 6:05AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) will host a conference call this afternoon to discuss the strategic acquisition of all U.S. rights to Contrave® and the Mysimba® commercialization and distribution agreement with Valeant Pharmaceuticals International, Inc. for Central and Eastern Europe.
OREX: 0.56 (unch)
Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in the United States
PR Newswire - Tue Mar 15, 6:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) (collectively "Takeda"
, today announced they have agreed to terminate the Amended and Restated Collaboration Agreement for CONTRAVE® (naltrexone HCl / bupropion HCl), the market leading national branded prescription treatment option for certain overweight and obese adults for chronic weight management. Completion of the transaction is subject to the parties' receipt of clearance under the Hart-Scott-Rodino Antitrust Improvement Act.
OREX: 0.56 (unch)
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Pharmaceuticals for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) for 18 Central and Eastern European Countries and Turkey
PR Newswire - Tue Mar 15, 6:00AM CDT
Orexigen Therapeutics, Inc. (NASDAQ:OREX) today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. The distribution agreement between Valeant Holdings Ireland and Orexigen's wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., includes 12 countries where Mysimba has been approved for marketing in the European Union (EU): Greece, Slovenia, Slovakia, Czech Republic, Hungary, Croatia, Lithuania, Estonia, Poland, Latvia, Bulgaria, and Romania. The agreement also extends to several non-EU countries where Valeant will apply for marketing authorization: Serbia, Bosnia and Herzegovina, Albania, Macedonia, Montenegro, Kosovo and Turkey. Orexigen expects Valeant to launch in the 12 EU countries in the second half of this year.
OREX: 0.56 (unch), VRX.TO: 34.05 (-1.05)
Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicine
PR Newswire - Tue Mar 15, 6:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the United States rights to Contrave® (naltrexone HCl / bupropion HCl extended release), the market leading branded prescription medicine for the treatment of obesity. The acquisition is subject to the parties' receipt of clearance under the Hart-Scott-Rodino Antitrust Improvement Act ("HSR Act" . Upon completion of the acquisition, including the agreed upon transition period, Orexigen will own all rights to Contrave in nearly all global territories.
OREX: 0.56 (unch)
Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Full Year 2015 Financial Results on February 26, 2016
PR Newswire - Fri Feb 19, 7:30AM CST
Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the fourth quarter and full year 2015 on Friday, February 26 before the market opens. Following the announcement, Orexigen will provide a business update and discuss the financial results in a live webcast and conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).
OREX: 0.56 (unch)
Here's Why Arena Pharmaceuticals Lost 17% of Its Value in January
George Budwell, The Motley Fool - Motley Fool - Tue Feb 09, 9:23AM CST
ARNA data by YCharts What: According to data provided by S&P Global Market Intelligence , shares of Arena Pharmaceuticals dropped by more than 17% in January. Given the lack of negative catalysts during the month, its poor showing...
OREX: 0.56 (unch), ARNA: 1.97 (+0.06)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2016
M2 - Thu Feb 04, 10:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/8tsk82/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles (Sample List) - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Cellnovo - CeQur - Flamel Technologies - Generex Biotechnology Corporation - GlaxoSmithKline PLC - Halozyme Therapeutics - Insulet - Insuline Medical Ltd. - Intarcia Therapeutics, Inc. - Janssen Research & Development - Johnson & Johnson - Novo Nordisk - Oramed Pharmaceuticals - Orexigen Therapeutics, Inc. - Owen Mumford - PhaseBio Pharmaceuticals - Pfizer - Prometheon Pharma - Roche Diagnostics - Sanofi - Valeritas - ViaCyte, Inc. (formerly Novocell) - Vivus, Inc. - vTv Therapeutics (formerly TransTech Pharma) - Ypsomed Holding For more information visit http://www.researchandmarkets.com/research/8tsk82/diabetes
OREX: 0.56 (unch), JNJ: 108.20 (-0.78), ABT: 41.83 (+0.18), VTVT: 5.16 (-0.09), NVO: 54.19 (-0.06), ORMP: 6.66 (-0.14), AMGN: 149.93 (+0.45), GSK: 40.55 (-0.15)
Orexigen Therapeutics to Speak at Upcoming Investor Conferences
PR Newswire - Tue Feb 02, 3:15PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows:
OREX: 0.56 (unch)
Biotech's Dumbest CEO Moves in 2015
Kristine Harjes, The Motley Fool - Motley Fool - Sat Jan 30, 12:01PM CST
Entering a new year means turning over a new leaf. Or at least that's what a handful of biotech CEOs would have you believe. Last year was an exciting one to follow the biotech sector, and it was largely filled with really exceptional leaders making...
OREX: 0.56 (unch), MNKD: 1.61 (-0.07), SNY: 40.16 (-0.53)
Why Zafgen Inc's Stock Is in the Red Today
Brian Feroldi, The Motley Fool - Motley Fool - Mon Jan 25, 11:25AM CST
What: Shares of Zafgen , a clinical-stage biopharmaceutical company developing therapies to treat obesity, dropped more than 10% in early morning trading on Monday after the investment research firm Kerrisdale Capital published a less than...
ZFGN: 6.68 (+0.37), OREX: 0.56 (unch)
3 Stocks I Would Avoid at All Costs
Timothy Green, Matthew DiLallo, and Brian Feroldi, The Motley Fool - Motley Fool - Sun Jan 24, 6:51AM CST
Image source: Elliot Brown via Flickr. There's nothing more dangerous for investors than being overly optimistic about a lackluster company. A bull argument can be constructed for any stock, but ignoring the risks can be catastrophic. Everyone...
OREX: 0.56 (unch), P: 8.95 (-0.55), CHK: 4.12 (+0.11)
8 Stocks Under $10 Making Big Moves Higher
at The Street - Fri Jan 22, 6:14AM CST
These stocks trading for less than $10 a share are within range of triggering big breakouts.
OREX: 0.56 (unch), DSX: 2.67 (+0.17), PN: 7.70 (+0.11), RICE: 13.96 (+0.43), ACTG: 3.79 (-0.12), FCX: 10.34 (+0.05), GNCA: 7.74 (+3.77), CLBS: 0.75 (-0.04)
Stocks To Watch: Market Update on Today's Stocks on the Move
ACCESSWIRE - Tue Mar 22, 12:00PM CDT
MIAMI, FL / ACCESSWIRE / March 22, 2016 / Top Nasdaq Stocks is issuing a report on three stocks to watch. OREX, SXE, NETE, and BBLU have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
NETE: 0.31 (-0.12), OREX: 0.56 (unch), SXE: 1.05 (-0.03), BBLU: 0.04 (-0.01)
The Zacks Analyst Blog Highlights: GW Pharma, Orexigen, Gilead and Regeneron
Zacks Equity Research - Zacks Investment Research - Thu Mar 17, 8:30AM CDT
The Zacks Analyst Blog Highlights: GW Pharma, Orexigen, Gilead and Regeneron
OREX: 0.56 (unch), GILD: 91.86 (-0.11), GWPH: 72.15 (+1.23), REGN: 360.44 (+0.76)
Orexigen Buys U.S. Rights to Contrave, Inks Deal in the EU
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 3:50PM CDT
Orexigen (OREX) has regained U.S. rights to Contrave from Takeda Pharmaceutical and inked a deal with Valeant Pharmaceuticals to commercialize the drug in the EU.
OREX: 0.56 (unch), VRX: 26.30 (-0.77), AMAG: 23.40 (+1.28)
Biotech Stock Roundup: GW Pharma Soars on Epidiolex Data, Gilead's Zydelig in Trouble?
Arpita Dutt - Zacks Investment Research - Wed Mar 16, 10:56AM CDT
Despite some positive updates from companies like GW Pharma (GWPH), the overall performance of the sector remained weak.
OREX: 0.56 (unch), VRTX: 79.49 (+1.09), GWPH: 72.15 (+1.23), GILD: 91.86 (-0.11), SRPT: 19.52 (+0.25), ABBV: 57.12 (+0.12), REGN: 360.44 (+0.76)
Valeant and Avon slump while Apple and Mead Johnson rise
AP - Tue Mar 15, 3:51PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq stock market:
DSW: 27.64 (-0.22), OREX: 0.56 (unch), VRX: 26.30 (-0.77), AVP: 4.81 (+0.11), MJN: 84.97 (-0.02), DOV: 64.33 (unch), AAPL: 108.99 (-0.57), MS: 25.01 (-0.06), VRX.TO: 34.05 (-1.05)
Valeant shocks with missed 4Q results, slashed 2016 guidance
By LINDA A. JOHNSON - AP - Tue Mar 15, 3:44PM CDT
Shares of Valeant Pharmaceuticals crashed Tuesday after the embattled drugmaker failed to reassure investors that it's getting back on track and even conceded for the first time that it's technically in danger of defaulting on its debt.
OREX: 0.56 (unch), VRX: 26.30 (-0.77), VRX.TO: 34.05 (-1.05)
Four Companies Added To Today's Stock Watchlist on Tuesday March 15, 2016
ACCESSWIRE - Tue Mar 15, 9:47AM CDT
MIAMI, FL / ACCESSWIRE / March 15, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. BLRX, OREX, SZYM, and ESI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OREX: 0.56 (unch), ESI: 3.09 (-0.02), BLRX: 1.02 (-0.01), SZYM: 2.03 (+0.21)
Orexigen Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Today to Discuss Acquisition of U.S. Rights to Contrave® (naltrexone HCl / bupropion HCl extended release) and Central and Eastern Europe Distribution Agreement with Valeant
PR Newswire - Tue Mar 15, 6:05AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) will host a conference call this afternoon to discuss the strategic acquisition of all U.S. rights to Contrave® and the Mysimba® commercialization and distribution agreement with Valeant Pharmaceuticals International, Inc. for Central and Eastern Europe.
OREX: 0.56 (unch)
Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in the United States
PR Newswire - Tue Mar 15, 6:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) (collectively "Takeda"
, today announced they have agreed to terminate the Amended and Restated Collaboration Agreement for CONTRAVE® (naltrexone HCl / bupropion HCl), the market leading national branded prescription treatment option for certain overweight and obese adults for chronic weight management. Completion of the transaction is subject to the parties' receipt of clearance under the Hart-Scott-Rodino Antitrust Improvement Act. OREX: 0.56 (unch)
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Pharmaceuticals for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) for 18 Central and Eastern European Countries and Turkey
PR Newswire - Tue Mar 15, 6:00AM CDT
Orexigen Therapeutics, Inc. (NASDAQ:OREX) today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. The distribution agreement between Valeant Holdings Ireland and Orexigen's wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., includes 12 countries where Mysimba has been approved for marketing in the European Union (EU): Greece, Slovenia, Slovakia, Czech Republic, Hungary, Croatia, Lithuania, Estonia, Poland, Latvia, Bulgaria, and Romania. The agreement also extends to several non-EU countries where Valeant will apply for marketing authorization: Serbia, Bosnia and Herzegovina, Albania, Macedonia, Montenegro, Kosovo and Turkey. Orexigen expects Valeant to launch in the 12 EU countries in the second half of this year.
OREX: 0.56 (unch), VRX.TO: 34.05 (-1.05)
Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicine
PR Newswire - Tue Mar 15, 6:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the United States rights to Contrave® (naltrexone HCl / bupropion HCl extended release), the market leading branded prescription medicine for the treatment of obesity. The acquisition is subject to the parties' receipt of clearance under the Hart-Scott-Rodino Antitrust Improvement Act ("HSR Act"
. Upon completion of the acquisition, including the agreed upon transition period, Orexigen will own all rights to Contrave in nearly all global territories. OREX: 0.56 (unch)
Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Full Year 2015 Financial Results on February 26, 2016
PR Newswire - Fri Feb 19, 7:30AM CST
Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the fourth quarter and full year 2015 on Friday, February 26 before the market opens. Following the announcement, Orexigen will provide a business update and discuss the financial results in a live webcast and conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).
OREX: 0.56 (unch)
Here's Why Arena Pharmaceuticals Lost 17% of Its Value in January
George Budwell, The Motley Fool - Motley Fool - Tue Feb 09, 9:23AM CST
ARNA data by YCharts What: According to data provided by S&P Global Market Intelligence , shares of Arena Pharmaceuticals dropped by more than 17% in January. Given the lack of negative catalysts during the month, its poor showing...
OREX: 0.56 (unch), ARNA: 1.97 (+0.06)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2016
M2 - Thu Feb 04, 10:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/8tsk82/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles (Sample List) - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Cellnovo - CeQur - Flamel Technologies - Generex Biotechnology Corporation - GlaxoSmithKline PLC - Halozyme Therapeutics - Insulet - Insuline Medical Ltd. - Intarcia Therapeutics, Inc. - Janssen Research & Development - Johnson & Johnson - Novo Nordisk - Oramed Pharmaceuticals - Orexigen Therapeutics, Inc. - Owen Mumford - PhaseBio Pharmaceuticals - Pfizer - Prometheon Pharma - Roche Diagnostics - Sanofi - Valeritas - ViaCyte, Inc. (formerly Novocell) - Vivus, Inc. - vTv Therapeutics (formerly TransTech Pharma) - Ypsomed Holding For more information visit http://www.researchandmarkets.com/research/8tsk82/diabetes
OREX: 0.56 (unch), JNJ: 108.20 (-0.78), ABT: 41.83 (+0.18), VTVT: 5.16 (-0.09), NVO: 54.19 (-0.06), ORMP: 6.66 (-0.14), AMGN: 149.93 (+0.45), GSK: 40.55 (-0.15)
Orexigen Therapeutics to Speak at Upcoming Investor Conferences
PR Newswire - Tue Feb 02, 3:15PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows:
OREX: 0.56 (unch)
Biotech's Dumbest CEO Moves in 2015
Kristine Harjes, The Motley Fool - Motley Fool - Sat Jan 30, 12:01PM CST
Entering a new year means turning over a new leaf. Or at least that's what a handful of biotech CEOs would have you believe. Last year was an exciting one to follow the biotech sector, and it was largely filled with really exceptional leaders making...
OREX: 0.56 (unch), MNKD: 1.61 (-0.07), SNY: 40.16 (-0.53)
Why Zafgen Inc's Stock Is in the Red Today
Brian Feroldi, The Motley Fool - Motley Fool - Mon Jan 25, 11:25AM CST
What: Shares of Zafgen , a clinical-stage biopharmaceutical company developing therapies to treat obesity, dropped more than 10% in early morning trading on Monday after the investment research firm Kerrisdale Capital published a less than...
ZFGN: 6.68 (+0.37), OREX: 0.56 (unch)
3 Stocks I Would Avoid at All Costs
Timothy Green, Matthew DiLallo, and Brian Feroldi, The Motley Fool - Motley Fool - Sun Jan 24, 6:51AM CST
Image source: Elliot Brown via Flickr. There's nothing more dangerous for investors than being overly optimistic about a lackluster company. A bull argument can be constructed for any stock, but ignoring the risks can be catastrophic. Everyone...
OREX: 0.56 (unch), P: 8.95 (-0.55), CHK: 4.12 (+0.11)
8 Stocks Under $10 Making Big Moves Higher
at The Street - Fri Jan 22, 6:14AM CST
These stocks trading for less than $10 a share are within range of triggering big breakouts.
OREX: 0.56 (unch), DSX: 2.67 (+0.17), PN: 7.70 (+0.11), RICE: 13.96 (+0.43), ACTG: 3.79 (-0.12), FCX: 10.34 (+0.05), GNCA: 7.74 (+3.77), CLBS: 0.75 (-0.04)
